Moderna Inc (MRNA)

130.85
-1.21(-0.92%)
Pre Market
130.65
-0.20(-0.15%)
- Real-time Data
  • Volume:
    5,320,851
  • Day's Range:
    126.28 - 133.00
  • 52 wk Range:
    119.01 - 496.71

MRNA Overview

Prev. Close
132.06
Day's Range
126.28-133
Revenue
22.6B
Open
130.98
52 wk Range
119.01-496.71
EPS
34.01
Volume
5,320,851
Market Cap
51.94B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
6,837,295
P/E Ratio
3.85
Beta
1.71
1-Year Change
-22.69%
Shares Outstanding
397,759,517
Next Earnings Date
Aug 10, 2022
What is your sentiment on Moderna?
or
Market is currently closed. Voting is open during market hours.

Moderna Inc News

Moderna Inc Analysis

Moderna Inc Company Profile

Moderna Inc Company Profile

Employees
2700

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellStrong SellNeutral
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong SellStrong SellSell
  • Moderna (NASDAQ:MRNA) CEO Stéphane Bancel announced his plan to donate to charity all of the after-tax proceeds of the original stock options he received upon joining the biotechnology company in 2013.The donation is expected to amount to about $355 million (assuming the stock is priced at around $140 per share), and after $280 million in tax payments.this should tell you a little something about the people in this company
    0
    • disbide all the hoopla for this technology it seems that the results thusfar are at best mixed. 3-4 company's are making tons of money BUT looks like results are at best quite mild therefore risky..
      0
      • this is a company with huge potential there cash alone should excite you
        0
    • Buy now.
      2
      • Come to papa
        0
        • NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / The nonprofit scientific research organization IAVI and Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant screenings are soon to start for a Phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research (CFHR) in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa.
          4
          • 'cause of the new variant of covid, Asians are losing their hair (I'm seriously), ok?
            3
            • cmon baby 10
              1
              • Now buy…
                4
                • why is this not scrambling yet ???
                  0
                  • When number of Shares Outstanding is gradually shrinking.. I love it
                    3